Academic Journal
Q1Cancer Genetics
About Cancer Genetics
About Cancer Genetics
Cancer Genetics is a peer-reviewed scholarly journal published by Elsevier B.V. (United States). It focuses on Q1. Publication coverage spans 2011-2026.
Key indicators: ISSN 2210-7762, 2210-7770; H-index 59.
Understanding This Journal's Metrics
Journal metrics help researchers assess fit, but they must be interpreted in context:
- H-index (59): Strong citation impact — 59 articles cited at least 59 times each, reflecting solid influence.
Publishing in Cancer Genetics
An established venue in its field. The journal welcomes solid, well-executed research. Ensure your manuscript fits the stated scope and follows author guidelines carefully.
- Scope fit: Confirm your research aligns with Q1. Off-scope manuscripts are typically desk-rejected quickly.
- Author guidelines: Follow formatting, reference style, and article-type requirements exactly — non-compliant manuscripts may be returned without review.
Is This Journal Right for Your Paper?
- Audience match: Will the journal's readers cite and build on your findings?
- Timeline: Higher-tier journals mean longer review and higher rejection risk. Balance prestige against your schedule.
- Indexing: Confirm indexing in Web of Science, Scopus, and PubMed (if biomedical) meets your institutional requirements.
- Open access needs: Check funder mandates and whether the journal offers compliant OA options.
Frequently Asked Questions
What is the ISSN of Cancer Genetics?
2210-7762, 2210-7770.
Who publishes Cancer Genetics?
Elsevier B.V..
What are Cancer Genetics's metrics?
H-index 59.
Is Cancer Genetics peer-reviewed?
Yes — it is a peer-reviewed scholarly journal indexed in major academic databases.
Source-backed journal facts
Topics in published research
Cancer Genomics and Diagnostics; Acute Myeloid Leukemia Research; Genomic variations and chromosomal abnormalities; Acute Lymphoblastic Leukemia research; Chronic Myeloid Leukemia Treatments; Diverse Scientific and Economic Studies.
OpenAlex classifies topics from published works. These topics are not the publisher’s official aims and scope.
Reported open-access list prices
3,320.00 USD; 3,110.00 EUR; 2,660.00 GBP; 411,780.00 JPY
APC list prices reported by OpenAlex, which obtains this information from DOAJ. Confirm current charges, taxes, waivers and eligibility with the publisher; this is not a fee quotation.
Source: OpenAlex source record. Retrieved 2026-10-03. Source record updated 2026-10-02. OpenAlex metrics are different from SCImago metrics and the Clarivate Journal Impact Factor.
Journal Metrics
Quartile, SJR and the listed SCImago H-index use the 2025 imported SCImago dataset. A quartile may vary by subject category. Values without a source or reporting year are unverified historical entries. Verify the current Journal Impact Factor with Clarivate or the publisher before using it.
Aims & Scope
The publisher’s official aims and scope have not yet been verified for this profile. Use the journal website to check subject fit and accepted article types before submitting.
Recent Research Articles
Latest publications matched automatically by ISSN.
Neuroendocrine prostate cancer converges on a fetal pulmonary neuroendocrine-like program
Wenchang Yue, Natasha Kyprianou, Ashutosh K. Tewari, Babu J. Padanilam et al.
2026-11 · DOI: 10.1016/j.cancergen.2026.09.011Long-read discovery in cancer cell lines defines a cis-spliced fusion RNA panel and its clinical associations across TCGA
Han-Ying Jhuang, Li-Tzu Wang
2026-11 · DOI: 10.1016/j.cancergen.2026.08.007MAGEA4 promotes gastric cancer progression by inducing chromosomal instability through the STAU1/c-Myc axis
Hong Deng, Ziwen Long, Cuiping Ren, Chenlong Song et al.
2026-11 · DOI: 10.1016/j.cancergen.2026.08.006The value of age stratification in evaluating canonical ALT genomic alterations in osteosarcoma
Songxiahe Zhao, Jinrui Lin, Yibin Du
2026-11 · DOI: 10.1016/j.cancergen.2026.09.006Integrative analysis of immune-cell eQTLs and Mendelian randomization identifies genetically supported genes associated with breast cancer susceptibility
Fulei Han, Rongrong Zhao, Haining Yu, Xuehao Cui et al.
2026-11 · DOI: 10.1016/j.cancergen.2026.09.007Spectrum of germline variants in moderate to high penetrance non-BRCA breast cancer susceptibility genes in a Pakistani early-onset cohort
Humaira Saleem, Mahrukh Nasir, Samra Khan, Muhammad Irfan et al.
2026-11 · DOI: 10.1016/j.cancergen.2026.09.009Integrated genomic and machine learning analyses identify SPOP as a candidate biomarker associated with tumor–immune features in nasopharyngeal carcinoma
Mengcheng Li, An Yi, Chunling Jiang
2026-11 · DOI: 10.1016/j.cancergen.2026.09.012The senescence ecosystem in genomic and epigenomic evolution during inflammation-associated carcinogenesis
Yingying Cao, Kai Guo, Dekun Wang, Zhongqiu Wang et al.
2026-11 · DOI: 10.1016/j.cancergen.2026.09.005From genotype to outcome in optic pathway gliomas: Biology, biomarkers, targeted therapy, and future directions
Eduardo Jahir Angulo-De La Cruz, Galilea Magaña-Curiel, Rafel Luis Aguirre-Guillén, Víctor Ulises Rodríguez-Machuca et al.
2026-11 · DOI: 10.1016/j.cancergen.2026.08.004eIF3A Promotes the Warburg Effect in Cervical Cancer through m6A-dependent Translational Regulation of ENO1
Linjuan Cai, Yu Jiang, Lingfeng Gu, Feiyang Li et al.
2026-11 · DOI: 10.1016/j.cancergen.2026.08.005Clinicopathological characteristics and tumor-detected genetic variations in Chinese patients with ductal carcinoma in situ of the breast
Yajie Zhao, Chunrui Pu, Chongjian Zhang, Zhenzhen Liu et al.
2026-11 · DOI: 10.1016/j.cancergen.2026.09.004Concurrent BCR::ABL1 and SET::NUP214 fusions in blast-phase chronic myeloid leukemia
Meenakkshy Manoharan, FNU Alnoor, Ping Yang, Catalina Amador-Ortiz et al.
2026-11 · DOI: 10.1016/j.cancergen.2026.08.008Genetic risk factors in Early-Onset Gastric Cancer: A systematic review and meta-analysis
Fabiana Sousa, Giovana Mori, Ana Silva, Daniela Silva et al.
2026-11 · DOI: 10.1016/j.cancergen.2026.09.003Senescent fibroblasts as drivers of malignant progression in gastric cancer
Yusheng Luo, Li Zhong, Kean Mu, You Li et al.
2026-11 · DOI: 10.1016/j.cancergen.2026.09.001Constitutional 10q25.1 microdeletion in siblings with oncologic findings: A tumor-germline interpretation challenge
Mohammad Karam Chaaban, Ehab Y. Harahsheh, DeAnna M. Weaver, Robert S. Platou et al.
2026-11 · DOI: 10.1016/j.cancergen.2026.09.002Genotype-by-regional ancestry proxy interactions at 8q24 reveal association heterogeneity in prostate cancer risk
Gha-hyun Jeffrey Kim
2026-11 · DOI: 10.1016/j.cancergen.2026.09.008CXCL8⁺HIF-1α⁺ macrophages define a disease-associated myeloid state during colorectal tumorigenesis
Baohui Song, Xucheng Huo, Haojun Li, Jiashaer Bahetinuer et al.
2026-10 · DOI: 10.1016/j.cancergen.2026.10.002Dual-Target Regulation of Prostate Cancer Genetic Dependencies by a Programmable Tetrahedral DNA Nanostructure
Zhen Hang, Hongkai Wang, Liu Yu, Shiwei Liu et al.
2026-10 · DOI: 10.1016/j.cancergen.2026.09.010Clinical Spectrum of Heterozygous LZTR1 Variation in a Schwannomatosis-Clinic Cohort: A Descriptive Study of Multisystem Features
Mohammad Karam Chaaban, Bukola A. Olarewaju, David Melville, Ehab Harahsheh et al.
2026-10 · DOI: 10.1016/j.cancergen.2026.10.004Genomic rearrangements define a distinct biological state in neuroblastoma
Giuseppe D’Alterio, Vincenzo Aievola, Giampiero Pirozzi, Laura De Rosa et al.
2026-10 · DOI: 10.1016/j.cancergen.2026.10.005Reviews
Community Reviews
Version History
October 9, 2026 at 7:55 pm
September 25, 2026